Acorda Therapeutics Gets a New CFO

Acorda Therapeutics (NASDAQ: ACOR  ) today announced its selection of a new CFO. Michael Rogers replaces David Lawrence, who has been named chief of business operations.  

Rogers has more than 20 years experience in the biopharmaceutical industry. Prior to joining Acorda, he was CFO and executive vice president of BG Medicine. He also served as CFO of Indevus Pharmaceuticals, which is now a unit of Endo Health Solutions.

Rogers will be paid an annual salary of $400,000 and be eligible to earn a bonus of up to 50% of that amount (this will be prorated for 2013), according to an SEC filing from the company. He will also be paid a signing bonus of $100,000, which is "subject to repayment under certain circumstances on a pro rata basis over a four-year period." Additionally, he will eligible for stock options. Lastly, the company has agreed to cover "the reasonable cost" of an apartment for its new CFO.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2671164, ~/Articles/ArticleHandler.aspx, 12/21/2014 1:59:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement